Thread Embedding Acupuncture Added to Antihistamine Treatment for Chronic Urticaria
Evaluation of the Efficacy and Safety of Thread Embedding Acupuncture Combined With an H1 Antihistamine for the Treatment of Chronic Urticaria
This study will test whether adding thread embedding acupuncture to an antihistamine helps adults with chronic hives whose symptoms remain bothersome despite taking the antihistamine. In thread embedding acupuncture, a clinician uses a needle to place a small dissolvable thread at an acupuncture point. The comparison procedure uses the same acupuncture points and a needle, without placing a thread. Both groups take cetirizine.
The researchers plan to enroll 124 adults at three hospitals in Ho Chi Minh City, Vietnam. Participants will be assigned by chance to one of the two groups. They will receive two procedures, two weeks apart. Participants and the people who assess their symptoms will not know which procedure they received. The main assessment compares changes in hives and itching after four weeks. The study will also assess quality of life, a blood marker called total immunoglobulin E, additional antihistamine use, side effects, and whether symptoms return during follow-up through week 8.
Tutkimuksen yleiskatsaus
Tila
Tila
Ehdot
Ehdot
Interventio / Hoito
Interventio / Hoito
Yksityiskohtainen kuvaus
This multicenter, randomized, sham-controlled, parallel-group trial compares polydioxanone (PDO) thread embedding acupuncture plus cetirizine with sham thread embedding acupuncture plus cetirizine. Eligible adults will complete a 7-day run-in with oral cetirizine 10 mg daily and a daily hives and itch diary. Participants with a 7-day Urticaria Activity Score (UAS7) of at least 16 and a weekly itch score of at least 8 after run-in are eligible for randomization.
The trial plans to randomize 124 participants in a 1:1 ratio using concealed block randomization through REDCap. Participants and outcome assessors are masked to allocation. The statistician will analyze coded groups. Clinicians performing the procedure know the assignment. Procedures are scheduled at baseline and week 2, with a 4-week treatment period and a further 4 weeks of follow-up. The primary analysis compares change from baseline in UAS7 at week 4. Other assessments include UAS7 at weeks 2 and 8, urticaria-related quality of life, serum total IgE, rescue medication use, adverse events, and symptom recurrence. Analyses are planned on an intention-to-treat basis.
Opintotyyppi
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Ilmoittautuminen
Vaihe
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskeluyhteys
Opiskeluyhteys
- Nimi: Sang Thanh Do, MD, MSc
- Puhelinnumero: +84 948 561 030
- Sähköposti: dtsang@ump.edu.vn
Opiskelupaikat
-
-
-
Ho Chi Minh City, Vietnam
- Ho Chi Minh City Traditional Medicine Hospital, Outpatient Department
-
Ho Chi Minh City, Vietnam
- Le Van Thinh Hospital, Department of Dermatology
-
Ho Chi Minh City, Vietnam
- University Medical Center Ho Chi Minh City, Branch 3
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Age 18 years or older and willing to provide written informed consent.
- Chronic urticaria diagnosed according to the EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline. Transient wheals and itching occur at least daily for more than 6 weeks despite prior or current use of an H1 antihistamine, without serious systemic symptoms. Individual wheals resolve within 30 minutes to 24 hours.
- UAS7 of at least 16 and weekly itch score of at least 8 after the 7-day run-in.
- No previous thread embedding acupuncture.
Exclusion Criteria:
- Urticaria with an identified cause, including physical or mechanical urticaria.
- Warning signs of systemic or autoinflammatory disease (e.g., Schnitzler syndrome or cryopyrin-associated periodic syndromes), or urticarial vasculitis.
- Cutaneous mast cell disease or erythema multiforme.
- Current or prior severe associated symptoms such as laryngeal edema, acute angioedema, anaphylaxis, or bradykinin-mediated angioedema including hereditary angioedema.
- Other chronic pruritic skin disease that could interfere with assessment.
- History of allergy to implant materials, especially absorbable suture or catgut, or a predisposition to keloid formation.
- Current or recent immunosuppressive therapy or systemic corticosteroids within 2 to 4 weeks (or 30 days) before participation, as specified in the protocol.
- Biologics such as omalizumab, leukotriene receptor antagonists, or H2 antihistamines within 7 to 14 days before screening or randomization, as specified in the protocol.
- H1 antihistamine use above the recommended dose within 3 days before screening.
- Psychotropic medication within the preceding month.
- Malignancy or severe endocrine disorder.
- Serious cardiovascular or cerebrovascular disease, diabetes mellitus, severe hepatic or renal failure, or a hematopoietic disorder.
- Severe debilitation with reduced immune resistance.
- Other serious systemic autoimmune disease, such as systemic lupus erythematosus.
- Cognitive impairment, psychiatric illness, or a communication barrier that prevents participation in the treatment procedures.
- A nonabsorbable implant at the intended procedure site.
- Pregnancy, breastfeeding, or plans to become pregnant during the study.
- Participation in another clinical trial in the preceding 3 months.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Kaksinkertainen
Aseiden lukumäärä
Aseet ja interventiot
Osallistujaryhmä / ArmOsallistujaryhmä / Arm |
Interventio / HoitoInterventio / Hoito |
|---|---|
|
Kokeellinen: PDO Thread Embedding Acupuncture Plus Cetirizine
Participants receive polydioxanone (PDO) thread embedding acupuncture at baseline and week 2, plus oral cetirizine as background treatment. |
An absorbable monofilament polydioxanone (PDO) thread is implanted at seven bilateral acupuncture points (14 sites) at baseline and week 2. Both arms receive cetirizine 10 mg orally each morning during the 7-day run-in and 4-week treatment period. Additional cetirizine use for rescue is recorded. |
|
Huijausvertailija: Sham Thread Embedding Acupuncture Plus Cetirizine
Participants receive a sham procedure at the same acupuncture points at baseline and week 2. The clinician uses an empty needle, so no thread is implanted. Participants also receive oral cetirizine as background treatment. |
Both arms receive cetirizine 10 mg orally each morning during the 7-day run-in and 4-week treatment period. Additional cetirizine use for rescue is recorded. The clinician inserts and withdraws an empty needle at the same acupuncture points at baseline and week 2. The procedure leaves no implanted thread. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change From Baseline in 7-Day Urticaria Activity Score (UAS7) at Week 4
Aikaikkuna: Baseline and week 4
|
UAS7 is the sum of participant-reported daily hive and itch severity scores over seven consecutive days. The total ranges from 0 to 42, with higher scores indicating more severe symptoms. Change is calculated as the follow-up score minus baseline. |
Baseline and week 4
|
Toissijaiset tulostoimenpiteet
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change From Baseline in UAS7 at Weeks 2 and 8
Aikaikkuna: Baseline and weeks 2 and 8
|
UAS7 is the sum of participant-reported daily hive and itch severity scores over seven consecutive days. The total ranges from 0 to 42, with higher scores indicating more severe symptoms. Change is calculated as the follow-up score minus baseline. |
Baseline and weeks 2 and 8
|
|
Change From Baseline in Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) Score
Aikaikkuna: Baseline and weeks 2, 4, and 8
|
Participants complete the disease-specific questionnaire about how chronic urticaria affected their lives in the preceding two weeks. Higher scores indicate greater impairment. Change is calculated as the follow-up score minus baseline. |
Baseline and weeks 2, 4, and 8
|
|
Change From Baseline in Serum Total Immunoglobulin E (IgE)
Aikaikkuna: Baseline and week 4
|
Serum total IgE is measured by enzyme-linked immunosorbent assay (ELISA) and reported in IU/mL. Change is calculated as the week 4 concentration minus baseline. |
Baseline and week 4
|
|
Proportion of Participants With Adverse Events
Aikaikkuna: From baseline through week 8
|
The study records adverse events and serious adverse events in each group during treatment and follow-up. Event severity is graded using the protocol-specified CTCAE criteria. |
From baseline through week 8
|
|
Proportion of Participants Reporting Recurrence or Flare of Urticaria Symptoms
Aikaikkuna: Weeks 4 through 8
|
Participants are contacted by telephone at week 8 using a standardized script to determine whether symptoms returned or flared during the post-treatment follow-up. |
Weeks 4 through 8
|
|
Number of Rescue Cetirizine Tablets Used
Aikaikkuna: From baseline through week 4
|
The total number of additional cetirizine tablets taken for symptom relief beyond the scheduled background dose is compared between groups. |
From baseline through week 4
|
Muut tulostoimenpiteet
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Association of Baseline UAS7, Serum Total IgE, and Disease Duration With UAS7 at Week 4
Aikaikkuna: Baseline and week 4
|
A multivariable linear regression will estimate the association of each baseline factor with week 4 UAS7, adjusting for study group and site. |
Baseline and week 4
|
Yhteistyökumppanit ja tutkijat
Sponsori
Sponsori
Tutkijat
Tutkijat
- Päätutkija: Sang Thanh Do, MD, MSc, University of Medicine and Pharmacy at Ho Chi Minh City
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Opiskelun aloitus
Ensisijainen valmistuminen (Arvioitu)
Ensisijainen valmistuminen
Opintojen valmistuminen (Arvioitu)
Opintojen valmistuminen
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Ensimmäinen Lähetetty
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin päivitys julkaistu
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Patologiset prosessit
- Krooninen sairaus
- Sairauden ominaisuudet
- Immuunijärjestelmän sairaudet
- Yliherkkyys, välitön
- Yliherkkyys
- Ihosairaudet
- Urtikaria
- Ihotaudit, verisuonisairaudet
- Patologiset tilat, merkit ja oireet
- Iho- ja sidekudostaudit
- Krooninen urtikaria
- Heterosykliset yhdisteet, 1-rengas
- Heterosykliset yhdisteet
- Piperatsiinit
- Hydroksitsiini
- Setiritsiini
Muut tutkimustunnusnumerot
Muut tutkimustunnusnumerot
- 4861/ĐHYD-HĐĐĐ
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .